Dataset related to the article "Cyclophilin A Inhibition as Potential Treatment of Human Aortic Valve Calcification"

This record contains raw data related to the article"Cyclophilin A Inhibition as Potential Treatment of Human Aortic Valve Calcification".

Abstract

Calcific aortic valve stenosis (AS) is a pathological condition that affects about 3% of the population, representing the most common valve disease. The main clinical feature of AS is represented by the impaired leaflet motility, due to calcification, which leads to the left ventricular outflow tract obstruction during systole. The formation and accumulation of calcium nodules are driven by valve interstitial cells (VICs). Unfortunately, to date, the in vitro and in vivo studies were not sufficient to fully recapitulate all the pathological pathways involved in AS development, as well as to define a specific and effective pharmacological treatment for AS patients.

Cyclophilin A (CyPA), the most important immunophilin and endogenous ligand of cyclosporine A (CsA), is strongly involved in several detrimental cardiovascular processes, such as calcification. To date, there are no data on the CyPA role in VIC-mediated calcification of aortic valve in AS. Here, we aimed to identify the role of CyPA in AS by studying VIC calcification, in vitro.

In this study, we found that i) CyPA is up-regulated in stenotic valves of AS patients, ii) pro-calcifying medium promotes CyPA secretion by VICs, iii) in vitro treatment of VICs with exogenous CyPA strongly stimulates calcium deposition, and iv) exogenous CyPA inhibition mediated by CsA analogue MM284 abolished in vitro calcium potential. Thus, CyPA represents a biological target that may act as a novel candidate in the detrimental AS development and its inhibition may provide a novel pharmacological approach for AS treatment.